Patient Care Online: Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis
by Grace Halsey
Alphyn Biologics has begun patient dosing in its global CLEAR-AD1 phase 2b clinical trial evaluating zabalafin hydrogel for treatment of atopic dermatitis (AD). The randomized, double-blind, vehicle-controlled study is currently enrolling patients in Australia, with plans to expand to US and European sites later this year, according to the company’s April 8 news release.
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195